Does Empagliflozin Improve Outcomes After Acute MI?

Empagliflozin did not reduce a composite endpoint of heart failure hospitalization or all-cause death, but HF hospitalizations occurred less often with the drug than placebo.

Sodium–glucose cotransporter-2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with type 2 diabetes, chronic kidney disease, and heart failure (HF). Patients with acute myocardial infarction (AMI) are at increased risk for HF and death, but data on SGLT2 inhibitors in this population are lacking. In an industry-funded, randomized trial (EMPACT-MI; NCT04509674), researchers compared the SGLT2 inhibitor empagliflozin (10 mg/day) with placebo in 6522 patients who had been hospitalized for AMI (74% with ST-segment elevation) within the past 14 days and who had a left-ventricular ejection fraction <45% or signs or symptoms of congestion requiring treatment.

During a median follow-up of 17.9 months, the empagliflozin and placebo gro…

Reviewing Author

Shea E Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Shea E Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Does Empagliflozin Improve Outcomes After Acute MI?

Topics

Reviewing Author